Omico

What Omico does

Omico is an independent, Australian not-for-profit precision oncology organization headquartered in Sydney, operating the country's largest cancer genomics initiative (PrOSPeCT) and coordinating a national network of cancer institutes, clinicians, researchers, industry partners, and government. It serves patients with advanced, incurable, or poor-prognosis cancers by coordinating comprehensive genomic profiling (CGP) of their tumors, routing results through a Molecular Oncology Board for expert review, and identifying biomarker-matched treatments and clinical trial options. As of the latest reported metrics, 37,311 people have been referred to Omico programs, 24,984 have completed CGP, 17,654 (70.7%) have received a treatment recommendation, and 1,546 have accessed a clinical trial or matched therapy, with a referring clinician network of 1,567.

The core technology stack is anchored by comprehensive genomic profiling (delivered via Foundation Medicine and Australian state pathology services), a Molecular Oncology Board that reviews profiling results, and a multi-program clinical trial portfolio (CaSP, MoST, C1/C2/C3, MoST-LLy, ASPiRATION, SMOC+, RisC) that links patients to targeted therapies. The operations are supported by a Clinical Portal (clinical.omico.org.au) for clinician referrals and a unique real-world genomic dataset being expanded into a formal RWD offering as of June 2026. Underlying platform components include a clinician referral system, genomic data infrastructure (via BioGrid Australia), and biospecimen repositories accessible to research partners.

Omico does not generate revenue in the traditional commercial sense. Its operating model is funded primarily through a $71M AUD Federal Government commitment (PrOSPeCT 2.0, May 2026 through 2028/29), supplemented by state government funding (NSW Health, Northern Territory Government), federal research grants (MRFF, NHMRC), philanthropy (Minderoo Foundation, Cancer Research Foundation), and industry partnerships with major pharmaceutical companies (AstraZeneca, Pfizer, Bayer, MSD, Seagen, Chugai, Eisai, Sun Pharma, PharmaEngine). A new commercial revenue stream — real-world data and biospecimen access for pharma R&D — was launched in June 2026, signaling a partial pivot toward commercial monetization. Pricing is not publicly disclosed and services are provided at no direct cost to eligible patients. The go-to-market is sales-led through clinician referrals, with secondary channels for industry data partnerships and research collaboration.

Name

Omico

Legal name

Omico

Website

https://omico.com.au

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Omico is an Australian not-for-profit that runs the country's largest cancer genomics initiative, coordinating comprehensive genomic profiling, Molecular Oncology Board review, and biomarker-led clinical trial matching for patients with advanced or poor-prognosis cancers. It serves patients, 1,567 referring clinicians, and pharmaceutical partners across a national precision oncology network.

Ownership category

akta.pro rank

Product category

Precision Oncology Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Precision oncology programs
• Genomic profiling services
• Clinical trial matching
• Cancer biomarker testing
• Real-world data analytics

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Government Funding: Primary funding from Australian federal and state government sources, including the $71M Federal Government commitment to PrOSPeCT 2.0 until 2028/29. This supports national precision oncology program operations, clinical trials, and research initiatives.
2. Industry Partnerships: Pharmaceutical company partnerships for clinical trial coordination, drug development support, and real-world data collaborations. Companies including AstraZeneca, Bayer, Pfizer, MSD, and others participate in clinical studies.
3. Real-World Data Offerings: Expanded real-world data and biospecimen services for research, clinical development, and precision cancer care innovation, launched June 2026.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Omico operates a national precision oncology platform that coordinates comprehensive genomic profiling (CGP) for Australian cancer patients, matches eligible patients to biomarker-led clinical trials and targeted therapies through its Molecular Oncology Board, and curates a unique real-world genomic dataset and biospecimen repository to support research, clinical development, and health system reform. Services are delivered via clinician referrals under the flagship PrOSPeCT program and associated Cancer Screening Program (CaSP).

Product overview

Omico is an independent, not-for-profit organization providing a comprehensive precision oncology ecosystem. The platform operates as a multi-program portfolio anchored by PrOSPeCT (the flagship national precision oncology initiative) and its associated Cancer Screening Program (CaSP). These core programs are supported by the foundational MoST study and multiple clinical trial programs (C1, C2, C3, MoST-LLy, ASPiRATION). Additional offerings include real-world data services, biospecimen access for research, and a Molecular Oncology Board for treatment matching. The ecosystem coordinates comprehensive genomic profiling, biomarker-led clinical trials, and patient enrolment across Australia's cancer care network.

Differentiator

Problem solved

Functional benefit

Products and services

• PrOSPeCT (Program of Strategic Translation) Omico's landmark national precision oncology initiative and the largest cancer genomics initiative in Australia, providing a nationally coordinated platform to expand access to precision oncology, accelerate research, generate real-world data, and improve cancer care for Australian patients.
• Cancer Screening Program (CaSP) The screening program associated with PrOSPeCT, providing comprehensive genomic profiling and matching eligible patients with advanced, incurable, and poor-prognosis cancers to innovative clinical trials and treatment options through a clinician referral process.
• Molecular Screening and Therapeutics (MoST) Study The pioneering precision oncology study that used genomic profiling to understand molecular changes in cancer and match patients with biomarker-led therapies; foundational to the PrOSPeCT program.
• Surveillance Study in Multi-Organ Cancer Prone Syndromes (SMOC+) Research program investigating and evaluating surveillance practices used for people at high risk of multi-organ cancer, supporting personalized cancer risk management using heritable genetic information.
• Genetic Cancer Risk in the Young (RisC) Study Research program studying genetic variants that contribute to inherited cancer risk in young people, supporting personalized cancer risk management.
• Company Studies (C3) Clinical trial program coordinating company-sponsored precision oncology studies in partnership with pharmaceutical and biotechnology companies.
• Companion Studies (C2) Clinical trial program for companion studies supporting precision oncology drug development.
• MoST Core Studies (C1) Core clinical trial studies within the MoST precision oncology program, foundational to biomarker-led therapy research.
• MoST-LLy Clinical trial program within the MoST framework supporting biomarker-led precision oncology research.
• ASPiRATION Clinical trial program for aspiration studies supporting precision oncology research and treatment access.
• Real-World Data Offerings Data service providing access to a unique real-world genomic dataset built for precision oncology decisions, delivering patient-centered evidence to support research, inform policy, and improve health systems and clinical cancer care.
• Biospecimens for Research Research service providing access to biospecimens and associated clinical and genomic data to support research and enable discovery in precision oncology.
• Molecular Oncology Board Multidisciplinary expert board that reviews comprehensive genomic profiling results and identifies potential treatment and clinical trial options for patients, returning recommendations to the treating clinician.
• Clinical Portal Online portal enabling clinicians to access clinical resources, manage patient information, and coordinate genomic profiling and treatment matching through Omico's programs.

Quantifiable outcome

• 70.7% of participants who had comprehensive genomic profiling received a treatment recommendation
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

32 partnerships are on record, tiered core, major and minor.

• Australian Government - Department of HealthcoreStrategic or Co-development PartnerFederal government partner providing major funding including $71M commitment to PrOSPeCT 2.0 until 2028/29. Supports national precision oncology initiatives and health system reform.
• Garvan Institute of Medical ResearchcoreStrategic or Co-development PartnerLeading Australian medical research institute specializing in cancer, genomic, and molecular research. Part of the national network enabling precision oncology delivery.
• Peter MacCallum Cancer CentrecoreStrategic or Co-development PartnerAustralia's only public hospital dedicated to cancer treatment, research, and education. Key partner in delivering precision oncology clinical services.
• QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development PartnerProminent Australian medical research institute conducting cancer research and contributing to precision oncology programs.
• AstraZenecamajorStrategic or Co-development PartnerPharmaceutical company partner supporting clinical trials and precision oncology drug development through the C3 company studies program.
• Pfizer OncologymajorStrategic or Co-development PartnerPharmaceutical partner providing access to targeted therapies and supporting biomarker-led clinical trials in precision oncology.
• BayermajorStrategic or Co-development PartnerPharmaceutical company engaged in clinical studies and precision oncology treatment access through Omico's coordinated programs.
• MSDmajorStrategic or Co-development PartnerPharmaceutical company partner contributing to clinical trial ecosystem and precision oncology treatment options for Australian patients.
• Foundation MedicinemajorTechnology or IntegrationProvider of comprehensive genomic profiling technology and testing services used in Omico's precision oncology programs.
• NSW HealthcoreStrategic or Co-development PartnerNew South Wales government health department supporting regional precision oncology delivery through public health infrastructure.
• University of SydneymajorStrategic or Co-development PartnerMajor Australian university contributing research expertise and academic collaboration to precision oncology programs.
• UNSW SydneymajorStrategic or Co-development PartnerUniversity of New South Wales providing research collaboration and academic resources for cancer genomics research.
• Macquarie UniversitymajorStrategic or Co-development PartnerAustralian university partner contributing research capabilities to Omico's precision oncology ecosystem.
• Centre for Molecular OncologymajorTechnology or IntegrationSpecialized oncology center providing molecular profiling capabilities and clinical expertise for precision medicine.
• SeagenmajorStrategic or Co-development PartnerBiotechnology company contributing targeted therapy options and clinical trial participation to Omico programs.
• Chugai PharmaceuticalmajorStrategic or Co-development PartnerJapanese pharmaceutical company partner providing access to innovative cancer therapies and clinical development.
• EisaimajorStrategic or Co-development PartnerPharmaceutical company engaged in cancer therapy development through precision oncology clinical trials.
• Sun PharmamajorStrategic or Co-development PartnerGlobal pharmaceutical company contributing to clinical trial ecosystem and targeted therapy access.
• Canteen AustraliamajorStrategic or Co-development PartnerYouth cancer organization providing support and advocacy for young people affected by cancer, connecting to Omico's programs.
• The Leukaemia FoundationmajorStrategic or Co-development PartnerBlood cancer support organization connecting patients to precision oncology services and advocacy.
• NSW Health PathologymajorTechnology or IntegrationState pathology service providing laboratory testing and diagnostic capabilities for genomic profiling.
• SA PathologymajorTechnology or IntegrationSouth Australian pathology service supporting specimen processing and diagnostic services.
• Pathology QueenslandmajorTechnology or IntegrationQueensland state pathology service contributing to diagnostic infrastructure for precision oncology.
• PathWestmajorTechnology or IntegrationWestern Australian pathology service providing laboratory capabilities for genomic testing.
• Metro South HealthmajorStrategic or Co-development PartnerQueensland public health service contributing clinical facilities and patient access for precision oncology delivery.
• Health Central AdelaidemajorStrategic or Co-development PartnerSouth Australian local health network providing clinical services and patient access for cancer care.
• Royal Hobart HospitalmajorStrategic or Co-development PartnerTasmanian public hospital providing regional cancer care and access to precision oncology services.
• BioGrid AustraliamajorTechnology or IntegrationHealthcare data linkage organization providing data infrastructure and integration capabilities.
• Medicines AustraliamajorStrategic or Co-development PartnerIndustry peak body representing pharmaceutical companies in Australia, facilitating industry partnerships.
• Northern Territory GovernmentmajorStrategic or Co-development PartnerTerritorial government ensuring equitable access to precision oncology services across all Australian jurisdictions.
• Linear Clinical ResearchmajorStrategic or Co-development PartnerSpecialized clinical trial site organization supporting biomarker-led clinical studies.
• PharmaEngineminorStrategic or Co-development PartnerBiopharmaceutical company contributing to precision oncology drug development.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Guardant Health: US-based precision oncology company providing comprehensive genomic profiling and liquid biopsy tests for advanced cancer patients, directly comparable to Omico's CGP and biomarker-led treatment matching focus.
• Caris Life Sciences: US molecular profiling company offering comprehensive genomic and transcriptomic profiling plus clinical trial matching for cancer patients, similar in core service to Omico's CGP-led matching.
• Personalis: US-based genomics company focused on comprehensive molecular profiling including whole-genome and immune profiling for cancer patients, comparable in technology approach to Omico's CGP platform.
• Molecular Health: German company offering clinical genomics interpretation and treatment-matching software for oncology, comparable to the Molecular Oncology Board and bioinformatics interpretation Omico performs.
• Genomics England: UK government-backed initiative delivering whole-genome sequencing and clinical interpretation at national scale, with a comparable model of government funding and national mandate similar to Omico's PrOSPeCT.
• Hartwig Medical Foundation: Dutch not-for-profit foundation building a national cancer genomics database and offering whole-genome sequencing to support treatment decisions for metastatic cancer patients, structurally very similar to Omico's national NFP model.
• Tempus Labs: US precision medicine company combining genomic profiling, real-world data, and AI to match cancer patients to therapies and clinical trials, closely analogous to Omico's PrOSPeCT and RWD offerings.

Broad incumbents

• Exact Sciences: US publicly-traded cancer diagnostics company with broader screening and treatment-selection tests (Cologuard, Oncotype DX). Larger and broader than Omico but operates in the same genomic oncology decision-support category.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology and Omico's named technology partner. Operates at vastly larger scale globally and supplies the CGP technology underpinning Omico's service.

Emerging players

• Natera: US-based cell-free DNA and molecular diagnostics company with growing oncology footprint (Signatera MRD). Partial overlap with Omico's genomic profiling focus but with stronger commercial orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/omicoaustralia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omico